Clinical Trial

Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

Study acronym: CAPIO
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
1. To investigate the efficacy and safety of cabozantinib in patients with progressive HCC after ICI-based combination treatment. 2. To explore potential tissue and peripheral blood biomarkers associated with clinical benefits of cabozantinib, and resistance mechanisms of prior ICI and cabozantinib.
Trial Details
NCT Number NCT07151326
Lead Sponsor National Health Research Institutes, Taiwan
Collaborators: National Taiwan University Hospital, Taipei Veterans General Hospital, Taiwan, Tri-Service General Hospital (TSGH), Mackay Memorial Hospital, Chang Gung Memorial Hospital, China Medical University Hospital, Taichung Veterans General Hospital, National Cheng-Kung University Hospital
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 60 participants
Start Date 2025-09
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-03